UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

Blood, 2015-01, Vol.125 (2), p.304-315

2015

Volltextzugriff (PDF)

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

International journal of hematology, 2018-06, Vol.107 (6), p.681-688

2018

Volltextzugriff (PDF)

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

Leukemia, 2008-01, Vol.22 (1), p.87-95

2008

Volltextzugriff (PDF)

Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia

International journal of hematology, 2018-10, Vol.108 (4), p.411-415

2018

Volltextzugriff (PDF)

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

Viruses, 2022-03, Vol.14 (4), p.710

2022

Volltextzugriff (PDF)

TET2 mutation in diffuse large B-cell lymphoma

Journal of Clinical and Experimental Hematopathology, 2017, Vol.56(3), pp.145-149

2017

Volltextzugriff (PDF)

JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation

British journal of haematology, 2010-08, Vol.150 (3), p.334-344

2010

Volltextzugriff (PDF)

Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions

Biochemical and biophysical research communications, 2010-09, Vol.400 (2), p.252-257

2010

Volltextzugriff (PDF)

Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice

European journal of haematology, 2017-05, Vol.98 (5), p.501-507

2017

Volltextzugriff (PDF)

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

Blood, 2011-06, Vol.117 (25), p.6866-6875

2011

Volltextzugriff (PDF)

Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

Journal of clinical medicine, 2020-12, Vol.10 (1), p.105

2020

Volltextzugriff (PDF)

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

Journal of Clinical and Experimental Hematopathology, 2015, Vol.55(3), pp.145-149

2015

Volltextzugriff (PDF)

Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

International journal of hematology, 2012-09, Vol.96 (3), p.342-349

2012

Volltextzugriff (PDF)

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

Annals of Laboratory Medicine, 2017, 37(2), , pp.159-161

2017

Volltextzugriff (PDF)

Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation

Annals of hematology, 2012-10, Vol.91 (10), p.1633-1643

2012

Volltextzugriff (PDF)

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

European journal of haematology, 2009-10, Vol.83 (4), p.328-333

2009

Volltextzugriff (PDF)

Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice

American journal of hematology, 2007-09, Vol.82 (9), p.802-806

2007

Volltextzugriff (PDF)

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

Journal of Clinical and Experimental Hematopathology, 2015-12, Vol.55 (3), p.145-149

2015

Volltextzugriff (PDF)

Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture

International journal of clinical oncology, 2012-08, Vol.17 (4), p.336-340

2012

Volltextzugriff (PDF)

Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma

European journal of haematology, 2021-03, Vol.106 (3), p.398-407

2021

Volltextzugriff (PDF)

Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F

Blood, 2014-12, Vol.124 (21), p.162-162

2014

Volltextzugriff (PDF)

Outcome of allogeneic hematopoietic cell transplantation in patients with adult T‐cell leukemia

Hematological oncology, 2018-10, Vol.36 (4), p.651-655

2018

Volltextzugriff (PDF)

Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm

Anticancer research, 2017-07, Vol.37 (7), p.3841-3847

2017

Volltextzugriff (PDF)

TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation

Blood, 2011-11, Vol.118 (21), p.2471-2471

2011

Volltextzugriff (PDF)

NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

Blood, 2010-11, Vol.116 (21), p.4106-4106

2010

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(75)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(36)
Humans
(24)
Hematology
(20)
Female
(13)
Aged
(11)
Animals
(11)
Male
(11)
Mice
(11)
Middle Aged
(11)
Oncology
(11)
Adult
(9)
Biological And Medical Sciences
(8)
Mutation
(8)
Aged, 80 And Over
(7)
Janus Kinase 2 - Genetics
(7)
Medical Sciences
(7)
Prognosis
(7)
Cell Line
(6)
Hematologic And Hematopoietic Diseases
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

TET2 mutation in diffuse large B-cell lymphoma

JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation

Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions

Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture

Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma

Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F

Outcome of allogeneic hematopoietic cell transplantation in patients with adult T‐cell leukemia

Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm

TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation

NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

Suchergebnisse filtern